Therefore, inhibiting the circFGFR1/CXCR4 pathways in NSCLC cells may provide a novel opportunity to inhibit resistance to anti-PD-1 immunotherapy in the treatment of NCSLC. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.